In the six completed AWARD results, the majority of dulaglutide patients had HbA1c targets <7.0% (53.0 mmol/mol) and ≤6.5% (47.5 mmol/mol), which were superior to the active comparators (Exenatide, Glycine Insulin, Metformin, and Sitagliptin), with the most common adverse events being gastrointestinal AE, the lower rates of hypoglycemia [86,87,88]. This evidence concerns the gene INS and Hypoglycemia.